blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2061803

EP2061803 - PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  14.10.2022
Database last updated on 06.07.2024
FormerThe patent has been granted
Status updated on  12.07.2019
FormerGrant of patent is intended
Status updated on  07.12.2018
FormerExamination is in progress
Status updated on  17.04.2018
Most recent event   Tooltip14.10.2022Patent maintained (B2 publication)published on 16.11.2022  [2022/46]
Applicant(s)For all designated states
Ares Trading S.A.
Zone Industrielle de l'Ouriettaz
1170 Aubonne / CH
[2022/46]
Former [2009/22]For all designated states
Ares Trading S.A.
Zone Industrielle de l'Ouriettaz
1170 Aubonne / CH
Inventor(s)01 / EON-DUVAL, Alex
Rue de l'Union 18
1800 Vevey / CH
02 / LAMPROYE, Alain
Les Petites Bruyères
1699 Bouloz / CH
 [2009/22]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2022/46]
Former [2019/33]Merck Serono S.A. Intellectual Property
Terre Bonne Business Park A2
Route de Crassier 15
1162 Eysins / CH
Former [2009/22]Merck Serono SA - Geneva Intellectual Property
9, chemin des Mines
1202 Geneva / CH
Application number, filing date07802925.327.08.2007
[2009/22]
WO2007EP58887
Priority number, dateEP2006011961128.08.2006         Original published format: EP 06119611
US20060842542P06.09.2006         Original published format: US 842542 P
[2009/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008025748
Date:06.03.2008
Language:EN
[2008/10]
Type: A1 Application with search report 
No.:EP2061803
Date:27.05.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 06.03.2008 takes the place of the publication of the European patent application.
[2009/22]
Type: B1 Patent specification 
No.:EP2061803
Date:14.08.2019
Language:EN
[2019/33]
Type: B2 New European patent specification 
No.:EP2061803
Date:16.11.2022
Language:EN
[2022/46]
Search report(s)International search report - published on:EP06.03.2008
ClassificationIPC:C07K1/18, C07K1/36, C07K16/06
[2018/52]
CPC:
C07K1/18 (EP,KR,US); C07K1/22 (KR); C07K1/36 (EP,US);
C07K16/065 (EP,US); C07K16/18 (KR); C07K19/00 (KR)
Former IPC [2015/41]C07K1/18, C07K1/36, C07K16/00
Former IPC [2009/22]C07K1/36
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/33]
Former [2009/22]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL18.03.2009
BA18.03.2009
HR18.03.2009
MK18.03.2009
RS18.03.2009
TitleGerman:VERFAHREN ZUR AUFREINIGUNG VON FC-HALTIGEN PROTEINEN[2009/22]
English:PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS[2009/22]
French:PROCÉDÉ DE PURIFICATION DE PROTÉINES CONTENANT FC[2009/22]
Entry into regional phase18.03.2009National basic fee paid 
18.03.2009Designation fee(s) paid 
18.03.2009Examination fee paid 
Examination procedure18.03.2009Examination requested  [2009/22]
15.12.2009Despatch of a communication from the examining division (Time limit: M06)
14.06.2010Reply to a communication from the examining division
22.09.2015Despatch of a communication from the examining division (Time limit: M04)
11.01.2016Reply to a communication from the examining division
06.04.2018Despatch of a communication from the examining division (Time limit: M04)
03.07.2018Reply to a communication from the examining division
14.12.2018Communication of intention to grant the patent
01.03.2019Fee for grant paid
01.03.2019Fee for publishing/printing paid
01.03.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.12.2009
Opposition(s)Opponent(s)01  14.05.2020    ADMISSIBLE
Neuefeind, Regina
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Opponent's representative
Neuefeind, Regina
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 02  14.05.2020    ADMISSIBLE
Hoffmann Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 [N/P]
Former [2020/25]
Opponent(s)01  14.05.2020    ADMISSIBLE
Neuefeind, Regina
Maiwald Patentanwalts - und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Opponent's representative
Neuefeind, Regina
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 02  14.05.2020    ADMISSIBLE
Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB
Arabellastr. 30
81925 München / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
17.06.2020Invitation to proprietor to file observations on the notice of opposition
27.10.2020Reply of patent proprietor to notice(s) of opposition
16.11.2021Legal effect of interlocutory decision in opposition
16.11.2021Date of oral proceedings
30.03.2022Despatch of interlocutory decision in opposition
30.03.2022Despatch of minutes of oral proceedings
14.07.2022Despatch of communication that the patent will be maintained as amended
11.10.2022Fee for printing new specification paid
Fees paidRenewal fee
18.03.2009Renewal fee patent year 03
17.08.2010Renewal fee patent year 04
11.08.2011Renewal fee patent year 05
10.08.2012Renewal fee patent year 06
19.08.2013Renewal fee patent year 07
13.08.2014Renewal fee patent year 08
10.08.2015Renewal fee patent year 09
11.08.2016Renewal fee patent year 10
14.08.2017Renewal fee patent year 11
10.08.2018Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY14.08.2019
MC14.08.2019
RO14.08.2019
SI14.08.2019
BG14.11.2019
GR15.11.2019
IS14.12.2019
[2021/48]
Former [2021/26]CY14.08.2019
MC14.08.2019
RO14.08.2019
BG14.11.2019
GR15.11.2019
IS14.12.2019
Former [2020/36]MC14.08.2019
RO14.08.2019
BG14.11.2019
GR15.11.2019
IS14.12.2019
Former [2020/29]MC14.08.2019
RO14.08.2019
BG14.11.2019
GR15.11.2019
IS24.02.2020
Former [2020/24]RO14.08.2019
BG14.11.2019
GR15.11.2019
IS24.02.2020
Former [2020/23]RO14.08.2019
BG14.11.2019
GR15.11.2019
IS14.12.2019
Former [2020/12]BG14.11.2019
GR15.11.2019
IS14.12.2019
Former [2020/10]BG14.11.2019
Cited inInternational search[DY]WO9641624  (IMMUNEX CORP [US]) [DY] 1-25* page 13, line 32 - line 34; example 1 *;
 [Y]WO2004076485  (LONZA BIOLOGICS PLC [GB], et al) [Y] 1-25 * page 3, line 9 - line 19 * * page 12, line 21 - line 22 *;
 [Y]WO2005100394  (HOFFMANN LA ROCHE [CH], et al) [Y] 1-25 * claim - *;
 [Y]EP1614693  (KIRIN BREWERY [JP]) [Y] 1-25 * claim - *
OppositionWO9964462
 US6417335
 WO03002713
 US2003229212
 WO2004024866
 WO9918130
 WO9957134
 WO02094852
 WO2009017491
 WO2008025748
    - P Parren, Et Al, "Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more", MABS, (20170101), vol. 9, no. 6, pages 898 - 906, XP055704031

DOI:   http://dx.doi.org/10.1080/19420862.2017.1341029
    - Goyon Alexandre; Excoffier Melissa; Janin-Bussat Marie-Claire; Bobaly Balazs; Fekete Szabolcs; Guillarme Davy; Beck Alain, "Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS., ELSEVIER, AMSTERDAM., NL, NL, (20171015), vol. 1065, doi:10.1016/j.jchromb.2017.09.033, ISSN 1570-0232, pages 119 - 128, XP085233861

DOI:   http://dx.doi.org/10.1016/j.jchromb.2017.09.033
    - A Williams, Frasca, V., "lon-Exchange Chromatography", Current Protocols in Protein Science, (19990101), pages 8.2.1 - 8.2.30, XP055704027
    - FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotechnology and Genetic Engineering Reviews, (20010700), vol. 18, doi:10.1080/02648725.2001.10648017, pages 301 - 327, XP008034714

DOI:   http://dx.doi.org/10.1080/02648725.2001.10648017
    - P. W. Atkins, "Physical Chemistry. Third Edition. Passage", Oxford University Press, (19860101), page 666, XP055704023
    - "Ion Exchange Chromatography & Chromatofocusing - Principles and Methods", Amersham Biosciences, (20040000), pages 1 - 188
    - CHIODI et al., "Isoelectric focusing of monoclonal immunoglobulin G, A and M followed by detection with the avidin-biotin system", Electrophoresis, (19850000), vol. 6, doi:10.1002/elps.1150060305, pages 124 - 128, XP003022810

DOI:   http://dx.doi.org/10.1002/elps.1150060305
    - "Product Monograph of ORENCIA", Bristol -Myers Squibb Canada, (20190000), pages 1 - 73
    - C Jochheim, Et Al, "Separation of Enbrel® (rhuTNFR: Fc) Isoforms by Capillary Isoelectric Focusing", CE in Biotechnology: Practical Applications for Protein and Peptide Analyses, (20010101), vol. 53, pages s59 - s65, XP055739511
    - FENG LI et al, "Current therapeutic antibody production and process optimization", BIOPROCESSING: ADVANCES AND TRENDS IN BIOLOGICAL PRODUCTDEVELOPMENT, WILLIAMSBURG BIOPROCESSING FOUNDATION, US, US, (20050901), ISSN 1538-8786, pages 1 - 8, XP002519952
    - Mariana P. Miranda-Hernández et al, "Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization", BioMed Research International, Hindawi Publishing Corporation, (20150101), vol. 2015, doi:10.1155/2015/874916, ISSN 2314-6133, pages 1 - 7, XP055366650

DOI:   http://dx.doi.org/10.1155/2015/874916
    - WILLEN, "Identifizierung, Charakterisierung und funktionelle Analyse der Bindungspartner von APRIL und TACI auf Monozyten und Dendritischen Zellen", INAUGURAL-DISSERTATION zur Erlangung der Doktorwürde der Naturwissenschaftlich-Mathematischen-Gesamtfakultät der Ruprecht-Karls-Universität Heidelberg, Heidelberg, (20060500), pages 1 - 159
    - FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotechnology and Genetic Engineering Reviews, (20010000), vol. 18, no. 1, doi:10.1080/02648725.2001.10648017, pages 301 - 327, XP008034714

DOI:   http://dx.doi.org/10.1080/02648725.2001.10648017
    - Electrical conductivity of aqueous solutions, URL: https://sites.chem.colostate.edu/diverdi/all- cou rses/CRC%20refe rence%20data/electrical%20cond uctivity%20of%20aq ueous%20 solutions.pdf
    - CHIODI et al., "Isoelectric focusing of monoclonal immunoglobulin G, A and M followed by detection with the avidin-biotin system", Electrophoresis, (19850000), vol. 6, doi:10.1002/elps.1150060305, pages 124 - 128
    - C Jochheim, Et Al, "Separation of Enbrel® (rhuTNFR: Fc) Isoforms by Capillary Isoelectric Focusing", CE in Biotechnology: Practical Applications for Protein and Peptide Analyses, (20010101), vol. 53, pages s59 - s65
    - FENG LI et al, "Current therapeutic antibody production and process optimization", BIOPROCESSING: ADVANCES AND TRENDS IN BIOLOGICAL PRODUCTDEVELOPMENT, WILLIAMSBURG BIOPROCESSING FOUNDATION, US, US, (20050901), ISSN 1538-8786, pages 1 - 8
    - Mariana P. Miranda-Hernández et al, "Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization", BioMed Research International, Hindawi Publishing Corporation, (20150101), vol. 2015, doi:10.1155/2015/874916, ISSN 2314-6133, pages 1 - 7
    - FAHRNER et al., "Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes", Biotechnology and Genetic Engineering Reviews, (20010000), vol. 18, no. 1, doi:10.1080/02648725.2001.10648017, pages 301 - 327
    - P Parren, Et Al, "Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more", MABS, (20170101), vol. 9, no. 6, pages 898 - 906
    - Goyon Alexandre et al, "Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS., ELSEVIER, AMSTERDAM., NL, (20171015), vol. 1065, doi:10.1016/j.jchromb.2017.09.033, ISSN 1570-0232, pages 119 - 128
    - A Williams, Frasca, V., "lon-Exchange Chromatography", Current Protocols in Protein Science, (19990101), pages 8.2.1 - 8.2.30
    - P. W. Atkins, "Physical Chemistry. Third Edition. Passage", Oxford University Press, (19860101), page 666
    - Ghosc ct al.. Biotechnology and Bioengineering. Vol. 92. No. 6. December 20. 2005 (published online on October 4.2005). DOI: 10 1002/bit.20729
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.